Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins

Xenobiotica

Volumn 38, Issue 7-8, 2008, Pages 995-1021

  Young, J D ^a   Yao, S Y M ^a   Sun, L ^b   Cass, C E ^a   Baldwin, S A ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anticancer nucleoside drugs; Antiviral nucleoside drugs; Equilibrative; Equilibrative nucleoside transporter (ENT); Nucleobase; Nucleoside; Transporter

Indexed keywords

CAPECITABINE; CLADRIBINE; CLOFARABINE; CYTARABINE; DILAZEP; DIPYRIDAMOLE; DRAFLAZINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 3; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 4; FLUDARABINE; GEMCITABINE; IMATINIB; MEMBRANE PROTEIN; NUCLEOBASE TRANSPORTER; NUCLEOSIDE TRANSPORTER; TROXACITABINE;

CAENORHABDITIS ELEGANS; ENZYME KINETICS; ENZYME REGULATION; HUMAN; LYMPHATIC LEUKEMIA; NONHUMAN; ORTHOLOGY; PANCREAS ADENOCARCINOMA; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SACCHAROMYCES CEREVISIAE; STRUCTURE ACTIVITY RELATION;

EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; HUMANS; NEOPLASMS; NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS DISEASES;

EUKARYOTA; MAMMALIA; PROTOZOA;

EID: 48749085061     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250801927427     Document Type: Review

References (142)

1. Abdulla P, Coe IR. 2007. Characterization and functional analysis of the promoter for the human equilibrative nucleoside transporter gene, hENT1. Nucleosides, Nucleotides and Nucleic Acids 26:99-110.
2. Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S. 2003. Structure and mechanism of the lactose permease of Escherichia coli. Science 301:610-615.
3. Acimovic Y, Coe IR. 2002. Molecular evolution of the equilibrative nucleoside transporter family: identification of novel family members in prokaryotes and eukaryotes. Molecular Biology and Evolution 19:2199-2210.
4. Ackley MA, Governo RJ, Cass CE, Young JD, Baldwin SA, King A. 2003. Control of glutamatergic neurotransmission in the rat spinal dorsal horn by the nucleoside transporter ENT1. Journal of Physiology 548:507-517.
5. Antoshechkin I, Sternberg PW. 2007. The versatile worm: genetic and genomic resources for Caenorhabditis elegans research. Nature Review in Genetics 8:518-532.
6. Appleford PJ, Griffiths M, Yao SYM, Chomey EG, MacGregor D, Isaac RE, Coates D, Hope IA, Cass CE, Young JD, et al. 2004. Functional redundancy of two nucleoside transporters of the ENT family (CeENT1, CeENT2) required for development of Caenorhabditis elegans. Molecular Membrane Biology 21:247-259.
7. Arastu-Kapur S, Arendt CS, Purnat T, Carter NS, Ullman B. 2005. Second-site suppression of a non-functional mutation within the Leishmania donovani inosine-guanosine transporter. Journal of Biological Chemistry 280:2213-2219.
8. Arastu-Kapur S, Ford E, Ullman B, Carter NS. 2003. Functional analysis of an inosine-guanosine transporter from Leishmania donovani, the role of conserved residues, aspartate 389 and arginine 393. Journal of Biological Chemistry 278:33327-33333.
9. Arendt CS, Ri K, Yates PA, Ullman B. 2007. Genetic selection for a highly functional cysteine-less membrane protein using site saturation mutagenesis. Analytical Biochemistry 365:185-193.
10. Baldwin SA, Beal PR, Yao SYM, King AE, Cass CE, Young JD. 2004. The equilibrative nucleoside transporter family, SLC29. Pflügers Archiv European Journal of Physiology 447:735-743.
11. Baldwin SA, Mackey JR, Cass CE, Young JD. 1999. Nucleoside transporters: molecular biology and implications for therapeutic development. Molecular Medicine Today 5:216-224.
12. Baldwin SA, McConkey GA, Cass CE, Young JD. 2007. Nucleoside transport as a potential target for chemotherapy in malaria. Current Pharmaceutical Design 13:569-580.
13. Baldwin SA, Yao SYM, Hyde RJ, Ng AML, Foppolo S, Barnes K, Ritzel MWL, Cass CE, Young JD. 2005. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. Journal of Biological Chemistry 280:15880-15887.
14. Barnes K, Dobrzynski H, Foppolo S, Beal PR, Ismat F, Scullion ER, Sun L, Tellez J, Ritzel MWL, Claycomb WC, et al. 2006. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circulation Research 99:510-519.
15. Barrett M, Fairlamb AH. 1999. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitology Today 15:136-140.
16. Barros LF, Yudilevich DL, Jarvis SM, Beaumont N, Young JD, Baldwin SA. 1995. Immunolocalisation of nucleoside transporters in human placental trophoblast and endothelial cells: evidence for multiple transporter isoforms. Pflügers Archiv European Journal of Physiology 429:394-399.
17. Baxter G. 2002. Role of adenosine in delayed preconditioning of myocardium. Cardiovascular Research 55:483-494.
18. Berry ZA. 2002. Nucleoside transporters in the heart. PhD Thesis, University of Leeds, Leeds.
19. Bone DB, Robillard KR, Stolk M, Hammond JR. 2007. Differential regulation of mouse equilibrative nucleoside transporter 1 (mENT1) splice variants by protein kinase CK2. Molecular Membrane Biology 24:294-303.
20. Carter NS, Fairlamb AH. 1993. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361:173-176.
21. Carter NS, Mamoun BC, Liu W, Silva EO, Landfear SM, Goldberg DE, Ullman B. 2000. Isolation and functional characterization of the PfNT1 nucleoside transporter gene from Plasmodium falciparum. Journal of Biological Chemistry 275:10683-10691.
22. Cass CE. 1995. Nucleoside transport. In: Georgopapadakou NH, editor. Drug transport in antimicrobial and anticancer chemotherapy. New York, NY: Marcel Dekker. pp 403-451.
23. Cass CE, Belt JA, Harley E, Odegard R, Paterson ARP. 1985. Transport of adenosine and binding of nitrobenzylthioinosine (NBMPR) during the HeLa cell cycle. Proceedings of the Canadian Federation of Biological Societies 28:126.
24. Cass CE, Belt JA, Paterson. 1987. Adenosine transport in cultured cells. Cardiac electrophysiology and pharmacology of adenosine and ATP: basic and clinical aspects. Progress in Clinical and Biological Research 230:13-40.
25. Chen J, Rinaldo L, Lim SJ, Young H, Messing RO, Choi DS. 2007. The type 1 equilibrative nucleoside transporter regulates anxiety-like behaviour in mice. Genes, Brain, and Behavior 6:776-783.
26. Chiang C-W, Carter N, Sullivan Jr WJ, Donald RGK, Roos DS, Naguib FNM, el Kouni MH, Ullman B, Wilson CM. 1999. The adenosine transporter of Toxoplasma gondii, identification by insertional mutagenesis, cloning, and recombinant expression. Journal of Biological Chemistry 274:35255-35261.
27. Choi DS, Csacini MG, Mailliard W, Young H, Paredes P, McMahon T, Diamond I, Bonci A, Messing RO. 2004. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nature Neuroscience 7:855-861.
28. Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE. 2006. The role of human nucleoside transporters in cellular uptake of 4′-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine. Molecular Pharmacology 70:303-310.
29. Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE. 2002. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. In: Andersson B, Murray D, editors. Clinically relevant resistance in cancer chemotherapy. Boston, MA: Kluwer. pp 27-47.
30. Coe I, Zhang Y, McKenzie T, Naydenova Z. 2002. PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Letters 517:201-205.
31. Crawford CR, Patel DH, Naeve C, Belt JA. 1998. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. Journal of Biological Chemistry 273:5288-5293.
32. Damaraju VL, Elwi AN, Hunter C, Carpenter P, Santos C, Barron GM, Sun X, Baldwin SA, Young JD, Mackey JR, et al. 2007. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. American Journal of Physiology, Renal Physiology 293:F200-F211.
33. De Koning HP, Bridges DJ, Burchmore RJ. 2005. Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. FEMS Microbiology Review 29:987-1020.
34. Dennis DM, Raatikainen P, Martens JR, Belardinelli L. 1996. Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea-pig heart. Circulation 94:2551-2559.
35. Downie MJ, Saliba KJ, Bröer S, Howitt SM, Kirk K. 2008. Purine nucleobase transport in the intraerythrocytic malaria parasite. International Journal for Parasitology 38:203-209.
36. Downie MJ, Saliba KJ, Howitt SM, Broer S, Kirk K. 2006. Transport of nucleosides across the Plasmodium falciparum parasite plasma membrane has characteristics of PfENT1. Molecular Microbiology 60:738-748.
37. El Bissati K, Zufferey R, Witola WH, Carter NS, Ullman B, Mamoun C. 2006. The plasma membrane permease PfNT1 is essential for purine salvage in the human malaria parasite Plasmodium falciparum. Proceedings of the National Academy of Sciences, USA 193:9286-9291.
38. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schönfeld C, Löffler M, Reyes G, Duszenko M, Karhausen J, et al. 2005. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. Journal of Experimental Medicine 202:1493-1505.
39. Elwi AN, Damaraju VL, Baldwin SA, Young JD, Sawyer MB, Cass CE. 2006. Renal nucleoside transporters: physiological and clinical implications. Biochemistry and Cell Biology 84:844-858.
40. Endres CJ, SenGupta DJ, Unadkat JD. 2004. Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. Biochemical Journal 380:131-137.
41. Endres CJ, Unadkat JD. 2005. Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. Molecular Pharmacology 67:837-844.
42. Engel K, Wang J. 2005. Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Molecular Pharmacology 68:1397-1407.
43. Engel K, Zhou M, Wang J. 2004. Identification and characterization of a novel monoamine transporter in the human brain. Journal of Biological Chemistry 279:50042-50049.
44. Galmarini CM, Mackey JR, Dumontet C. 2002. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncology 3:415-424.
45. Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C. 2002. Potential mechanisms of resistance to cytarabine in AML patients. Leukemia Research 26:621-629.
46. Gati WP, Dagnino L, Paterson ARP. 1989. Enantiomeric selectivity of adenosine transport systems in mouse erythrocytes and L1210 cells. Biochemical Journal 263:957-960.
47. Gati WP, Paterson ARP, Belch AR, Chlumecky V, Larratt LM, Mant MJ, Turner AR. 1998. Es nucleoside transporter content of acute leukaemia cells: role in cell sensitivity to cytarabine (araC). Leukemia and Lymphoma 32:45-54.
48. Gati WP, Paterson ARP, Larratt LM, Turner AR, Belch AR. 1997. Sensitivity of acute leukaemia cells to cytarabine is a correlate of cellular es nucleoside transporter content measured by flow cytometry with SAENTA-fluorescein. Blood 90:346-353.
49. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, et al. 2006. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Research 66:3928-3935.
50. Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, Bowlin T. 2001. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemotherapy and Pharmacology 47:236-240.
51. Govindaraja NR, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD. 2007. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys and placenta. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 293:R1809-R1822.
52. Griffith DA, Jarvis SM. 1996. Nucleoside and nucleobase transport systems of mammalian cells. Biochimica et Biophysica Acta 1286):153-181.
53. Griffiths M, Beaumont N, Yao SYM, Sundaram M, Boumah CE, Davies A, Kwong FYP, Coe I, Cass CE, Young JD, et al. 1997a. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nature Medicine 3:89-93.
54. Griffiths M, Yao SYM, Abidi F, Phillips SEV, Cass CE, Young JD, Baldwin SA. 1997b. Molecular Cloning and characterization of a nitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochemical Journal 328:739-743.
55. +-nucleoside cotransporter rCNT1. Journal of Biological Chemistry 276:27981-27988.
56. Handa M, Choi DS, Caldeiro RM, Messing RO, Gordon AS, Diamond I. 2001. Cloning of a novel isoform of the mouse NBMPR-sensitive equilibrative nucleoside transporter (ENT1) lacking a putative phosphorylation site. Gene 262:301-307.
57. Horak J. 1997. Yeast nutrient transporters. Biochimica et Biophysica Acta 1331:41-79.
58. Huang M, Wang Y, Cogut SB, Mitchell BS, Graves LM. 2003. Inhibition of nucleoside transport by protein kinase inhibitors. Journal of Pharmacology and Experimental Therapeutics 304:753-760.
59. Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM. 2002. Inhibition of nucleoside transport by p38 MAPK inhibitors. Journal of Biological Chemistry 277:28364-28367.
60. Huang Y, Leimeux MJ, Song J, Auer M, Wang DN. 2003. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301:616-620.
61. Hyde RJ, Cass CE, Young JD, Baldwin SA. 2001. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure-function relationships and the identification of novel isoforms. Molecular Membrane Biology 18:53-63.
62. Jarvis SM, Young JD. 1987. Photoaffinity labelling of the nucleoside transporter. Pharmacology and Therapeutics 32:339-359.
63. Jennings LL, Hao CH, Cabrita MA, Vickers MF, Baldwin SA, Young JD, Cass CE. 2001. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology 40:722-731.
64. Keil GJ, DeLander GE. 1995. Time-dependent antinociceptive interactions between opioids and nucleoside transport inhibitors. Journal of Pharmacology and Experimental Therapeutics 274:1387-1392.
65. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Morizane C, Yamamoto N, Ikeda M, et al. 2006. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metabolism and Pharmacokinetics 21:248-256.
66. King AE, Ackey MA, Cass CE, Young JD, Baldwin SA. 2006a. Nucleoside transporters: from scavengers to novel therapeutic agents. Trends in Pharmacological Sciences 27:416-425.
67. King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, Mowles DA, Ng AM, Young JD, Cass CE. 2006b. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Molecular Pharmacology 69:346-353.
68. Kiss A, Farah K, Kim J, Garriock RJ, Drysdale TA, Hammond JR. 2000. Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochemical Journal 352:363-372.
69. Lai YR, Bakken AH, Unadkat JD. 2002. Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells - localization and vectorial transport studies. Journal of Biological Chemistry 277:37711-37717.
70. Lai YR, Tse CM, Unadkat JD. 2004. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. Journal of Biological Chemistry 279:4490-4497.
71. Lee EW, Lai YR, Zhang H, Unadkat JD. 2006. Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. Journal of Biological Chemistry 281:16700-16706.
72. Liu W, Boitz JM, Galazka J, Arendt CS, Carter NS, Ullman B. 2006. Functional characterization of nucleoside transporter gene replacements in Leishmania donovani. Molecular and Biochemical Parasitology 150:300-307.
73. Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, Koski SL, Coupland RW, Baldwin SA, Young JD, et al. 2002. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clinical Cancer Research 8:110-116.
74. Mackey JR, Yao SYM, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD. 1999. Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. Journal of the National Cancer Institute 91:1876-1881.
75. Mangravite LM, Xiao G, Giacomini KM. 2003. Localization of Human Equilibrative Nucleoside Transporters, hENT1 and hENT2. American Journal of Physiology. Renal Physiology 284:F902-F910.
76. Mani RS, Hammond JR, Marjan JM, Graham KA, Young JD, Baldwin SA, Cass CE. 1998. Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultures human choriocarconoma (BeWo) cells by functional reconstitution in proteoliposomes. Journal of Biological Chemistry 273:30818-30825.
77. Martin BJ, Lasley RD, Mentzer RM. 1997. Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine. American Journal of Physiology. Heart and Circulatory Physiology 41:H1857-H1865.
78. Mathew A, Grdisa M, Johnstone RM. 1993. Nucleosides and glutamine are primary energy substrates for embryonic and adult chicken red cells. Biochemistry and Cell Biology 71:288-295.
79. Matile P. 1969. Vacuoles as lysosomes of plant cells. Biochemical Journal 111:26P-27P.
80. Matovu E, Steward ML, Geiser F, Brun R, Mäser P, Wallace LJM, Burchmore RJ, Enyaru JCK, Barrett MP, Kaminsky R, et al. 2003. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryotic Cell 2:1003-1008.
81. Meckling-Gill KA, Guilbert L, Cass CE. 1993. CSF-1 stimulates nucleoside transport in S1 macrophages. Journal of Cellular Physiology 155:530-538.
82. Meester BJ, Shankley NP, Welsh NJ, Meijler FL, Black JW. 1998. Pharmacological analysis of the activity of the adenosine uptake inhibitor, dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea-pig. British Journal of Pharmacology 124:729-741.
83. Mubagwa K, Flameng W. 2001. Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovascular Research 52:25-39.
84. Murray AW. 1971. The biological significance of purine salvage. Annual Review of Biochemistry 40:811-826.
85. Musa H, Dobrzynski H, Berry Z, Abidi F, Cass CE, Young JD, Baldwin SA, Boyett MR. 2002. Immunocytochemical demonstration of the equilibrative nucleoside transporter rENT1 in rat sinoatrial node. Journal of Histochemistry and Cytochemistry 50:305-309.
86. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y. 2007. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. British Journal of Cancer 96:457-463.
87. Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, Yamazaki H, Eimoto T, Ueda R. 2007. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Letters 256:112-119.
88. Olah ME, Stiles GL. 2000. The role of receptor structure in determining adenosine receptor activity. Pharmacology and Therapeutics 85:55-75.
89. Ortiz D, Sanchez MA, Pierce S, Herrmann T, Kimblin N, Bouwer HGA, Landfear SM. 2007. Molecular genetic analysis of purine nucleobase transport in Leishmania major. Molecular Microbiology 64:1228-1243.
90. Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J, Ferrin TE, Herskowitz I, Giuacomini KM. 2003. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, hENT1. Pharmacogenetics 13:297-301.
91. Owen RP, Lagpacan LL, Taylor TR, De La Cruz M, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM. 2006. Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metabolism and Disposition 34:12-15.
92. Papageorgiou I, De Koning HP, Soteriadou K, Diallinas G. 2007. Kinetic and mutational analysis of the Trypanosoma brucei NBT1 nucleobase transporter expressed in Saccharomyces cerevisiae reveals structural similarities between ENT and MFS transporters. International Journal of Parasitology (Epub ahead of print).
93. Parker MD, Hyde RJ, Yao SYM, McRobert L, Cass CE, Young JD, McConkey GA, Baldwin SA. 2000. Identification of a nucleoside/nucleobase transporter from Plasmodium falciparum, a novel target for antimalarial chemotherapy. Biochemical Journal 349:67-75.
94. Pisoni RL, Thoene JG. 1989. Detection and characterization of a nucleoside transport system in human fibroblast lysosomes. Journal of Biological Chemistry 264:4850-4856.
95. Poon A, Sawynok J. 1998. Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 74:235-245.
96. Pressacco J, Wiley JS, Jamieson GP, Erlichman C, Hedley DW. 1995. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA-synthesis. British Journal of Cancer 72:939-942.
97. Rahn JJ, Kieller DM, Tyrrell DL, Gati WP. 1997. Modulation of the metabolism of beta-L-(-)-2′,3′-dideoxy-3′-thiacytidine by thymidine, fludarabine and nitrobenzylthioinosine. Antimicrobial Agents and Chemotherapy 41:918-923.
98. Reiman T, Clarke ML, Dabbagh L, Vsianska M, Coupland RW, Belch AR, Baldwin SA, Young JD, Cass CE, Mackey JR. 2002. Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease. Leukemia and Lymphoma 43:1435-1440.
99. +- nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (System cib). Journal of Biological Chemistry 276:2914-2927.
100. Sanchez MA, Tryon R, Green J, Boor I, Landfear SM. 2002. Six related nucleoside/nucleobase transporters from Trypanosoma brucei exhibit distinct biochemical functions. Journal of Biological Chemistry 277:21499-21504.
101. Sandoval IV, Martinez-Arca S, Valdueza J, Palacios S, Holman GD. 2000. Distinct reading of different structural determinants modulates the dileucine-mediated transport steps of the lysosomal membrane protein LIMPII and the insulin-sensitive glucose transporter GLUT4. Journal of Biological Chemistry 275:39874-39885.
102. Sawynok J. 1998. Adenosine receptor activation and nociception. European Journal of Pharmacology 347:1-11.
103. SenGupta DJ, Lum PY, Lai YR, Shubochkina E, Bakken AH, Schneider G, Unadkat JD. 2002. A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Biochemistry 41:1512-1519.
104. SenGupta DJ, Unadkat JD. 2004. Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Biochemical Pharmacology 67:453-458.
105. Shryock JC, Belardinelli L. 1997. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. American Journal of Cardiology 79(12A):2-10.
106. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. 2004. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clinical Cancer Research 10:6956-6961.
107. Sundaram M, Yao SYM, Ingram JC, Berry ZA, Abidi F, Cass CE, Baldwin SA, Young JD. 2001a. Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. Journal of Biological Chemistry 276:45270-45275.
108. Sundaram M, Yao SYM, Ng AML, Cass CE, Baldwin SA, Young JD. 2001b. Equilibrative nucleoside transporters: mapping regions of interaction for the substrate analogue nitrobenzylthioinosine (NBMPR) using rat chimeric proteins. Biochemistry 40:8146-8151.
109. Sundaram M, Yao SYM, Ng AML, Griffiths M, Cass CE, Baldwin SA, Young JD. 1998. Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. Journal of Biological Chemistry 273:21519-21525.
110. Szkotak AJ, Ng AML, Man SF, Baldwin SA, Cass CE, Young JD, Duszyk M. 2003. Coupling of CFTR-mediated anion secretion to nucleoside transporters and adenosine homeostasis in Calu-3 cells. Journal of Membrane Biology 192:169-179.
111. + current in human airway epithelial cells by exogenous and autocrine adenosine. American Journal of Physiology. Cell Physiology 281:C1991-C2002.
112. Tattersall MHN, Slowiaczek P, De Fazio A. 1983. Regional variation in human extracellular purine levels. Journal of Laboratory and Clinical Medicine 102:411-420.
113. Teodorescu O, Galor T, Pillardy J, Elber R. 2004. Enriching the sequence substitution matrix by structural information. Proteins 54:41-48.
114. Valdés R, Liu W, Ullman B, Landfear SM. 2006. Comprehensive examination of charged intramembrane residues in a nucleoside transporter. Journal of Biological Chemistry 281:22647-22655.
115. Valdés R, Vasudevan G, Conklin D, Landfear SM. 2004. Transmembrane domain 5 of the LdNT1. 1 nucleoside transporter is an amphipathic helix that forms part of the nucleoside translocation pathway. Biochemistry 43:6793-6802.
116. Vickers MF, Kumar R, Visser F, Zhang J, Charania J, Raborn RT, Baldwin SA, Young JD, Cass CE. 2002. Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae. Biochemistry and Cell Biology 80:639-644.
117. Vickers MF, Mani RS, Sundaram M, Hogue DL, Young JD, Baldwin SA, Cass CE. 1999. Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae - interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q). Biochemical Journal 339:21-32.
118. Vickers MF, Yao SYM, Young JD, Baldwin SA, Cass CE. 2000. Nucleoside transporter proteins of Saccharomyces cerevisiae: Demonstration of a transporter (FUI1) with high uridine selectivity in plasma membranes and a transporter (FUN26) with broad nucleoside selectivity in intracellular membranes. Journal of Biological Chemistry 275:25931-25938.
119. Vickers MF, Zhang J, Visser F, Tackaberry T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, Cass CE. 2004. Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae. Nucleosides, Nucleotides and Nucleic Acids 23:361-373.
120. Visser F, Baldwin SA, Isaac SA, Young JD, Cass CE. 2005a. Identification and mutational analysis of amino acid residues involved in dipyridamole interactions with human and Caenorhabditis elegans equilibrative nucleoside transporters. Journal of Biological Chemistry 280:11025-11034.
121. Visser F, Sun L, Damaraju V, Tackaberry T, Peng Y, Robins MJ, Baldwin SA, Young JD, Cass CE. 2007. Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity, protein folding and catalytic turnover. Journal of Biological Chemistry 282:14148-14157.
122. Visser F, Vickers MF, Ng AL, Baldwin SA, Young JD, Cass CE. 2002. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. Journal of Biological Chemistry 277:395-401.
123. Visser F, Zhang J, Raborn RT, Baldwin SA, Young JD, Cass CE. 2005b. Residue 33 of human equilibrative nucleoside transporter 2 is a functionally important component of both the dipyridamole and nucleoside binding sites. Molecular Pharmacology 67:1291-1298.
124. Ward JL, Leung GP, Toan SV, Tse CM. 2003. Functional analysis of site-directed glycosylation mutants of the human equilibrative nucleoside transporter-2. Archives of Biochemistry and Biophysics 411:19-26.
125. Ward JL, Sherali A, Mo Z-P, Tse C-M. 2000. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. Journal of Biological Chemistry 275:8375-8381.
126. Wiley JS, Woodruff RK, Jamieson GP, Firkin FC, Sawyer WH. 1987. Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia. Australian and New Zealand Journal of Medicine 17:379-386.
127. Williams JB, Lanahan AA. 1995. A mammalian delayed-early response gene encodes HNP36, a novel, conserved nucleolar protein. Biochemical and Biophysical Research Communications 213:325-333.
128. Wright AM, Gati WP, Paterson AR. 2000. Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia 14:52-60.
129. Wu SK, Ann DK, Kim KJ, Lee VH. 2005. Fine tuning of rabbit equilibrative nucleoside transporter activity by an alternatively spliced variant. Journal of Drug Targeting 13:521-533.
130. Xia L, Engel K, Zhou, Wang J. 2006. Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. American Journal of Physiology. Renal Physiology 292:F682-F690.
131. Xiao G, Wang J, Tangen T, Giacomini KM. 2001. A novel proton-dependent nucleoside transporter, CeCNT3, from Caenorhabditis elegans. Molecular Pharmacology 59:339-348.
132. Yao SYM, Ng AML, Muzyka WR, Griffiths M, Cass CE, Baldwin SA, Young JD. 1997. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. Journal of Biological Chemistry 272:28423-28430.
133. Yao SYM, Ng AML, Sundaram M, Cass CE, Baldwin SA, Young JD. 2001. Transport of antiviral 3′-deoxynucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced inXenopus oocytes. Molecular Membrane Biology 18:161-167.
134. Yao SYM, Ng AML, Vickers MF, Sundaram M, Cass EC, Baldwin SA, Young JD. 2002. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2 - chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. Journal of Biological Chemistry 277:24938-24948.
135. 140 in helix 4 as an exofacial cysteine residue within the substrate-translocation channel of rat equilibrative nitrobenzylthioinosine (NBMPR)-insensitive nucleoside transporter rENT2. Biochemical Journal 353:387-393.
136. Young JD, Cheeseman CI, Mackey JR, Cass CE, Baldwin SA. 2000. Molecular mechanisms of nucleoside and nucleobase transport. Current Topics in Membranes 50:329-378.
137. Young JD, Jarvis SM, Clanachan AS, Henderson JF, Paterson ARP. 1986. Nitrobenzylthioinosine - an in vivo inhibitor of pig erythrocyte energy metabolism. American Journal of Physiology 251:C90-C94.
138. 6-(p-azidobenzyl) adenosine and nitrobenzylthioinosine. Evidence that the transporter is a band 4.5 polypeptide. Journal of Biological Chemistry 258:2202-2208.
139. Young JD, Yao SYM, Cass CE, Baldwin SA. 2003. Equilibrative nucleoside transport proteins. Red cell transport in health and disease Berlin: Springer. pp 321-337.
140. Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. 2007. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Review 26:85-110.
141. Zhang YW, Shepel PN, Peeling J, Geiger JD, Parkinson FE. 2002. Effects of nitrobenzylthioinosine on adenosine levels and neuronal injury in rat forebrain ischemia. Neuroscience Research Communications 30:83-89.
142. Zhou M, Engel K, Wang J. 2006. Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain. Biochemical Pharmacology 73:147-154.